Covid-19 Associated Coagulopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

May 6, 2020

Primary Completion Date

April 16, 2021

Study Completion Date

April 16, 2021

Conditions
COVID 19 Associated Coagulopathy
Interventions
DRUG

Intermediate dose thromboprophylaxis

2\) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).

DRUG

Standard of Care thromboprophylaxis

Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).

Trial Locations (2)

52242

University of Iowa, Iowa City

54601

Gundersen Health System, La Crosse

All Listed Sponsors
lead

University of Iowa

OTHER

NCT04360824 - Covid-19 Associated Coagulopathy | Biotech Hunter | Biotech Hunter